Nanomedsyn
Develops M6PR-targeting glycoligands for biotech and pharmaceutical developers of targeted therapeutics
Highlights
- New on EvolcAdded 2026-11-15
About Nanomedsyn
NanoMedSyn develops AMFA glycoligands that use the mannose 6-phosphate receptor pathway to deliver therapeutic conjugates to disease-relevant cells and tissues. Applications include antibodies, enzymes, nanoparticles and other biologics.
The company develops the technology for therapeutic applications in oncology, immunology, inflammation and metabolic disorders. Its preclinical work includes a Pompe disease proof of concept, and AMFA-therapy has received Orphan Drug Designation from the EMA.
NanoMedSyn is based in Montpellier, France, and was founded in 2012.
Product: AMFA glycoligands and related technology for targeted delivery of therapeutic conjugates through the M6PR pathway.
Jobs at Nanomedsyn
Leadership
- Marcel Garcia · CEO and co-founder of NanoMedSynSource: company website
More biotech & pharma companies
Nanoreviv
Develops localized antibiotic formulations for pharmaceutical partners and patients with local infectionsYoung companyNew on EvolcNaobios
GMP development and manufacturing services for companies developing viral vaccines, vectors and other virus-based productsNaogen Pharma
Radiopharmaceutical laboratory for nuclear cardiology imaging and nuclear medicine partnersNew on EvolcNaolys
Plant cell culture ingredients for cosmetics brands, including hair, makeup and men's face care activesNBX Biosciences
Developing oral microbiome-based therapeutics for brain health and cognitive impairmentYoung companyNew on EvolcNeovirtech
Virology imaging and screening services for academic and industrial researchers developing antivirals, vaccines and gene therapiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Contact Form 7High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WPFormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
